- Home
- TAK vs CCEP Comparison
TAK vs CCEP Comparison
Compare TAK & CCEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- CCEP
- Stock Information
- Founded
- TAK 1781
- CCEP 1986
- Country
- TAK Japan
- CCEP United Kingdom
- Employees
- TAK N/A
- CCEP N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- CCEP Beverages (Production/Distribution)
- Sector
- TAK Health Care
- CCEP Consumer Staples
- Exchange
- TAK Nasdaq
- CCEP Nasdaq
- Market Cap
- TAK 42.5B
- CCEP 35.8B
- IPO Year
- TAK N/A
- CCEP 1987
- Fundamental
- Price
- TAK $13.32
- CCEP $76.65
- Analyst Decision
- TAK
- CCEP Strong Buy
- Analyst Count
- TAK 0
- CCEP 9
- Target Price
- TAK N/A
- CCEP $84.50
- AVG Volume (30 Days)
- TAK 1.8M
- CCEP 1.5M
- Earning Date
- TAK 01-30-2025
- CCEP 08-07-2024
- Dividend Yield
- TAK 4.74%
- CCEP 2.74%
- EPS Growth
- TAK 49.73
- CCEP N/A
- EPS
- TAK 1.27
- CCEP 3.75
- Revenue
- TAK $31,732,209,416.00
- CCEP $20,521,804,348.00
- Revenue This Year
- TAK $4.41
- CCEP $13.73
- Revenue Next Year
- TAK $1.09
- CCEP $5.46
- P/E Ratio
- TAK $20.89
- CCEP $20.76
- Revenue Growth
- TAK 9.43
- CCEP 6.31
- 52 Week Low
- TAK $12.58
- CCEP $64.25
- 52 Week High
- TAK $15.08
- CCEP $82.32
- Technical
- Relative Strength Index (RSI)
- TAK 40.07
- CCEP 46.51
- Support Level
- TAK $13.26
- CCEP $77.18
- Resistance Level
- TAK $13.42
- CCEP $79.71
- Average True Range (ATR)
- TAK 0.14
- CCEP 1.38
- MACD
- TAK -0.02
- CCEP -0.09
- Stochastic Oscillator
- TAK 7.95
- CCEP 37.24
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About CCEP Coca-Cola Europacific Partners plc
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe (80% of 2023 revenue and EBIT) and Australasia (20%).In 2023, CCEP sold 3.3 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume. Coke's largest bottler, Coca-Cola Femsa sold 4 billion unit cases (12%), and the third-largest, Coca-Cola HBC, serving Eastern Europe and North Africa, sold 2.8 billion unit cases (8%).TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.